SCHEMBL2979161

SCHEMBL2979161

Fc1ccc2nc(-c3ccccc3-c3ncc(Br)[nH]3)[nH]c2c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.54
METAP1 P53582 2/20 0.54
CBFB Q13951 1/20 0.54
AMY1A P0DUB6 10/20 0.52
CYP11B1 P15538 1/20 0.50
BACE1 P56817 1/20 0.49
KDR P35968 2/20 0.46
MET P08581 1/20 0.46
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 2/20 0.44
RAB9A P51151 2/20 0.44
PKM P14618 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TCF4 P15884 1/20 0.44
CTNNB1 P35222 1/20 0.44
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977718 0.81 AMY1A (0.56) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL2978439 0.77 CBFB (0.80) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL28487873 0.76 AMY1A (0.68) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL28477377 0.72 CYP11B1 (0.70) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL6158996 0.72 KDR (0.74) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL5118616 0.72 CDK1 (0.77) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL2315219 0.71 AMY1A (0.57) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL13658385 0.71 AMY1A (0.57) METAP2METAP1CBFBAMY1ACYP11B1
Hydrochloric Acid SCHEMBL5119587 0.71 CDK1 (0.75) METAP2METAP1CBFBAMY1ACYP11B1
SCHEMBL28492593 0.71 KDR (0.58) AMY1AKDRMETNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777051-B2 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2010-08-17 US disclosed
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2005-02-17 US disclosed
WO-2005002503-A2 ASYMMETRIC BENZIMIDAZOLES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038067-A1 Asymmetric benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNJ1, KCNJ11 METAP2 3453/4885METAP1 4171/4885CBFB 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.